Biogen Idec still on top in MS drug fight
36297
In early 2002, Serono Inc. launched an assault on the multiple sclerosis market n the United States with its drug Rebif, taking aim at the leader, Biogen Idec Inc.'s Avonex.
253298
The drug company pushes on after the Enhance trials.
371520
Biogen Idec Inc. won federal approval for its new anti-multiple sclerosis drug Antegren - the first new treatment for MS patients in eight years.
565353
If Biogen Idec Inc. is sold to a pharmaceuticals giant, as many biotech industry observers expect, it could spell the loss of yet another major corporate headquarters in Massachusetts, a blow to the state's prestige.
26798
Early yesterday evening, Biogen IDEC (Nasdaq: BIIB) and Elan (NYSE: ELN) announced that Tysabri had been approved by the FDA for the treatment of multiple sclerosis (MS).
312721
The biotechnology company reported fourth-quarter net income of $201.2 million on strong sales of its two leading drugs, Rituxan and Avonex.
81579
BOSTON  â Biogen Idec said on Wednesday its fourth-quarter profit rose 84 percent, topping expectations, driven by increased sales of its multiple sclerosis drugs Avonex and Tysabri.
214879
DUBLIN -- US drug company Biogen Idec is considering an all-share bid of more than 8.5 billion euros ($10.6 billion) for Irish peer Elan , a newspaper reported yesterday.
480434
Shares of Elan Corp., Ireland&#39;s biggest drugmaker, rose as much as 7.7 percent after a newspaper reported that the company&#39;s US partner Biogen Idec Inc.
482241
The drugmaker bumps into the FDA as it pushes to do more testing of Entereg.
132487
For those that missed it last night, Biogen Idec (BIIB:Nasdaq - news - research) and Elan Pharmaceuticals (ELN:NYSE ADR - news - research) received FDA approval for their new multiple sclerosis drug, now called Tysabri (formerly known as Antegren.
297310
U.S. regulators have approved wider use of Genentech Inc. and Biogen Idec Inc.'s drug Rituxan for patients with a type of lymphoma, the companies announced on Friday.
567020
U.S. drug company Biogen Idec is considering an all-share bid of more than 8.5 billion euros (&#36;10.6 billion) for Irish peer Elan, a newspaper reported on Sunday.
501444
The Food and Drug Administration has approved a new drug for multiple sclerosis that in clinical trials got better results than existing drugs in protecting against relapses.
357627
A top compound in development could become an important MS treatment.
267375
Investors in the biotechnology company Biogen Idec announced Wednesday that it had not received any definitive offers after putting itself up for sale two months ago.
463623
James C. Mullen,Biogen Idec Inc.Chief executive For Biogen Idec Inc., the return of the multiple sclerosis drug Tysabri to the market and continued sales growth for its cash cow, Avonex, were the highlights of 2006. Chief executive James C. Mullen recently spoke with Globe reporter Jeffrey Krasner about the company's progress and the challenges posed by the 2006 election.